Valneva announces positive Phase 2 results for tetravalent Shigella vaccine candidate S4V2
FROM THE WIRE · GLOBENEWSWIRE.COM
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive Phase 2 data for a vaccine candidate can support the shares of a small biotech.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Data come from an infant immunogenicity and safety trial and a controlled human infection model trial.
- 02The trials demonstrate a favorable safety profile.
- 03Encouraging immunogenicity and efficacy signals were observed.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets